

RESEARCH ARTICLE

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition *in vitro*

Lara Milian^{1,2}, Manuel Mata^{1,2,3*}, Javier Alcacer⁴, María Oliver¹, María Sancho-Tello^{1,2}, José Javier Martín de Llano^{1,2}, Carlos Camps⁵, José Galbis⁶, Julian Carretero⁷, Carmen Carda^{1,2}

1 Department of Pathology, Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain, **2** Research Institute of the University Clinical Hospital of Valencia (INCLIVA), Valencia, Spain, **3** Networking Research Center on Respiratory Diseases (CIBERER), ISCIII, Carretera Soller Bunyola, Mallorca, Illes Balears, Spain, **4** Patologica S.L. Legión Española Square, Valencia, Spain, **5** University General Hospital of Valencia, Valencia, Spain, **6** Alzira Hospital, Carretera de Corbera, Alzira, Valencia, Spain, **7** Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, Valencia, Spain

* manuel.mata@uv.es



OPEN ACCESS

Citation: Milian L, Mata M, Alcacer J, Oliver M, Sancho-Tello M, Martín de Llano JJ, et al. (2020) Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition *in vitro*. PLoS ONE 15(2): e0228909. <https://doi.org/10.1371/journal.pone.0228909>

Editor: Guillermo Velasco, Universidad Complutense de Madrid, SPAIN

Received: March 28, 2019

Accepted: January 27, 2020

Published: February 12, 2020

Copyright: © 2020 Milian et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by grants MAT2016-76039-C4-2-R (MST and CC) and PI16-01315 (MM) from the Ministry of Economy and Competitiveness of the Spanish Government and the Instituto de Salud Carlos III. CIBER-BBN and CIBERER are funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010,

Abstract

Background/Objective

Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, *e.g.*, cannabinoid receptors (*CB1* and *CB2*) agonists including tetrahydrocannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD confers greater benefits, as CBD enhances the effects of THC and reduces its psychotropic activity. We assessed the relationship between the expression levels of *CB1* and *CB2* to the clinical features of a cohort of patients with NSCLC, and the effect of THC and CBD (individually and in combination) on proliferation, EMT and migration *in vitro* in A549, H460 and H1792 lung cancer cell lines.

Methods

Expression levels of *CB1*, *CB2*, *EGFR*, *CDH1*, *CDH2* and *VIM* were evaluated by quantitative reverse transcription-polymerase chain reaction. THC and CBD (10–100 μ M), individually or in combination (1:1 ratio), were used for *in vitro* assays. Cell proliferation was determined by BrdU incorporation assay. Morphological changes in the cells were visualized by phase-contrast and fluorescence microscopy. Migration was studied by scratch recolonization induced by 20 ng/ml epidermal growth factor (EGF).

Results

The tumor samples were classified according to the level of expression of *CB1*, *CB2*, or both. Patients with high expression levels of *CB1*, *CB2*, and *CB1/CB2* showed increased

Consolider Program, CIBER Actions and the Instituto de Salud Carlos III, with assistance from the European Regional Development Fund.

Competing interests: The authors have declared that no competing interests exist.

survival reaching significance for *CB1* and *CB1/CB2* ($p = 0.035$ and 0.025 , respectively). Both cannabinoid agonists inhibited the proliferation and expression of *EGFR* in lung cancer cells, and CBD potentiated the effect of THC. THC and CBD alone or in combination restored the epithelial phenotype, as evidenced by increased expression of *CDH1* and reduced expression of *CDH2* and *VIM*, as well as by fluorescence analysis of cellular cytoskeleton. Finally, both cannabinoids reduced the *in vitro* migration of the three lung cancer cells lines used.

Conclusions

The expression levels of *CB1* and *CB2* have a potential use as markers of survival in patients with NSCLC. THC and CBD inhibited the proliferation and expression of *EGFR* in the lung cancer cells studied. Finally, the THC/CBD combination restored the epithelial phenotype *in vitro*.

Introduction

Lung cancer is the leading cause of cancer-related death; more than 1 million patients are diagnosed annually. In many cases, life expectancy is only a few months and the 5-year survival rate is $< 15\%$ [1–2]. Non-small cell lung cancer (NSCLC) represents 85% of all lung cancers and the most common subtypes are adenocarcinoma and squamous cell carcinoma [3]. Both subtypes are characterized by genetic abnormalities, which lead to alterations in signaling pathways that are targets for drug therapies [4]. All patients with NSCLC eventually develop resistance to antitumor agents, including endothelial growth factor receptor (EGFR) inhibitors and chemotherapeutics, possibly due to abnormal signal transduction and *EGFR* overexpression [5–7]. This necessitates the development of new complementary pharmacological agents.

The endocannabinoid system is composed of the G-protein-coupled receptors *CB1* and *CB2*, their endogenous ligands anandamide and 2-araquidonoglycerol, and their synthetic and degradative enzymes [8]. *CB1* receptor is expressed not only in the central nervous system, but also in other tissues and organs, where its activation exerts both central and peripheral effects [9]. *CB2* is expressed in immune cells, microglia, vascular smooth muscle cells, hepatic stellate cells, and endothelial cells. *CB2* modulates Ca^{2+} channels, mitogen-activated protein kinase activation, and cAMP production [9]. According to reports, both receptors are expressed in, for example, breast and prostate cancer, glioblastoma, rhabdomyosarcoma, and colorectal cancer cells [10–14].

Although *CB1* and *CB2* are expressed in a variety of cancer cell lines and types of tumors, including adenocarcinomas [15], the relationships of their expression levels with lesion characteristics and disease progression have not been investigated. We thus assessed the correlation between the expression levels of the two receptors and the disease and clinical characteristics of a cohort of patients with NSCLC.

Cannabinoid-receptor agonists have potential as complementary pharmacological agents for NSCLC due to their analgesic, antianorexic, antiemetic and antineoplastic properties. For example, cannabinoid receptor agonists modulate key signaling pathways—including the extracellular signal-related kinase (ERK), phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (p38 MAPK), and ceramide pathways—*in vitro* and *in vivo*, inducing apoptosis and inhibiting cancer dissemination [16–18]. Cannabinoids act on cannabinoid receptors and include endocannabinoids (produced naturally in the body of animals),

phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially). *Cannabis sativa* contains more than 150 cannabinoid agonists, including Δ^9 -tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol, cannabichrome, and cannabigerol [19]. Among these, THC and CBD have demonstrated antitumor efficacy against glioblastoma, leukemia, and melanoma, as well as cervical, breast, and prostate cancer [20]. THC is a partial agonist of *CB1* and *CB2* receptors, and induces analgesia and muscle relaxation, suppresses emesis and stimulates appetite; however, the psychotropic activity of THC limits its clinical use [21]. CBD has greater affinity for *CB2* than *CB1* [22]. It also stimulates vanilloid pain receptors (VR1) and inhibits the uptake of anandamide [23]. CBD has anti-inflammatory, neuroprotective, anticonvulsant, muscle-relaxant, and anti-psychotropic effects [22]. Combined use of THC and CBD confers greater benefits, as CBD enhances the effects of THC and reduces its psychotropic activity. Thereby, in rats, CBD administered with THC ameliorate adversely effect (e.g. dysphoria) often associated with THC alone and did not alter the discriminative stimulus effect of THC [24]. Moreover, this combination enhances anticancer activity compared with THC alone and reduces the doses of THC that are needed to inhibit tumor growth [25–27]. CBD has also been shown to alleviate some of the undesired effects of THC administration, such as convulsions, discoordination and psychotic events, and, therefore, improves the tolerance of cannabis-based medicines [25]. Moreover, the combined use of THC and CBD reduces cell viability and migration, and induces apoptosis in human glioblastoma [28]; however, its effect on NSCLC is unclear. We thus investigated the influence of *CB1* on the antineoplastic effects of THC in an *in vitro* model of lung cancer.

The epithelial-to-mesenchymal transition (EMT) involves complex phenotypic changes of tumor cells [29]. During the EMT, epithelial markers (including E-cadherin) are downregulated and mesenchymal markers (such as vimentin [*VIM*], N-cadherin, and smooth muscle alpha actin [*ASMA*]) are upregulated by the transcription factors snail, ZEB1, and ZEB2 in a manner involving transforming growth factor- β 1 (TGF- β 1) [30–32]. Ravi *et al.* assessed the effect of the *CB2* agonist JWH-015 on the EMT in A549 cells exposed to TGF- β 1, and in an *in vivo* model of tumorigenesis [4]. They found that JWH-015 inhibited EMTE in A549 cells and also reversed the mesenchymal nature of CALU-1 cells by downregulating *EGFR* signaling. JWH-015 decreased also migratory and invasiveness of A549 cells. In the present study, we also evaluated the effect of the non-selective cannabinoids agonists THC and CBD by separate or in combination on the EMT in three lung cancer cell lines and we explored the additive effect of CBD in combination with THC.

In this study, we investigated the correlation of the expression levels of *CB1* and *CB2* with the clinical and pathological features of 157 samples of well-characterized lung tumors. We determined the effect of the non-selective cannabinoid agonists CBD and THC by separate or in combination on cell proliferation, the expression of *EGFR*, the EMT and migration of A549, H460 and H1792 cells exposed to TGF- β or EGF. We found an additive effect of THC/CBD, which support the use of this combination in order to minimize the dose of THC and its psychotropic effects. The results emphasize the importance of the endocannabinoid system, as well as the potential use of *CB1* and *CB2* as biomarkers of survival in patients with NSCLC.

Materials and methods

Patients

We retrospectively analyzed 157 tumor samples from patients with NSCLC. The tumor samples were stored at -80° C. The clinical and histopathological features of the tumors are listed in Table 1. All of the subjects provided informed consent. The study was conducted in accordance with the Declaration of Helsinki and applicable local regulatory requirements and laws.

Table 1. Clinical and histopathological characteristics of the patients with NSCLC.

	N	%
Age (median)	61 (35–81)	
Gender		
Male	136	86.6
Female	21	13.4
Smoker		
Never	16	10.2
Ex-smoker	64	40.8
Active smoker	77	49.0
Stage		
IA	13	8.3
IB	62	39.5
IIA	5	3.2
IIB	29	18.5
IIIA	32	20.4
IIIB	12	7.6
IV	4	2.5
TNM		
T1	21	13.4
T2	88	56.1
T3	32	20.4
T4	16	10.2
N0	89	56.7
N1	21	13.4
N2	25	15.9
Nx	2	1.3
M0	151	96.2
M1	6	3.8
Grade		
Well-differentiated	23	14.6
Moderately differentiated	83	52.9
Poorly differentiated	51	32.5
Histology		
Epidermoid	79	50.3
Adenocarcinoma	57	36.3
Giant cells	5	3.2
Adenosquamous	6	3.8
Carcinoid	1	0.6
Microcytic	1	0.6
Non-differentiated	6	3.8
Neuroendocrine	2	1.3

<https://doi.org/10.1371/journal.pone.0228909.t001>

The procedures were approved by the Ethics Committee of the University General Hospital of Valencia (Spain).

Cannabinoids

THC and CBD were supplied by Sigma-Aldrich (Madrid, Spain). They were prepared at 150 mM amounts in ethanol and used individually or mixed 1:1 at concentrations of 10–100 μ M.

Cells and *in vitro* experiments

A549, H460 and H1792 human lung cancer cells were purchased from the American Type Culture Collection (Rockville, MD, USA). The cells were grown in 25 cm² culture flasks in Roswell Park Memorial Institute (RPMI) medium containing endotoxin-free fetal bovine serum (FBS, 5% for A549 and H460 cells, 10% for H1792 cells), L-glutamine (4 mM), penicillin (100 U/mL), streptomycin (10 µg/ml) and amphotericin B (0.25 µg/mL).

To assess the antitumor effect of THC and CBD, cells were exposed to 10–100 µM THC or CBD, individually or in combination (1:1 ratio) for 48 hours. Cell proliferation and the expression levels of *CB1*, *CB2*, and *EGFR* were evaluated. To analyze the effect of THC/CBD on the EMT, A549, H460 and H1792 cells were stimulated with TGF-β (15 ng/ml) in the presence or absence of 30 µM THC or 30 µM CBD alone or in combination at 10 µM for 48 hours. The effects on the cytoskeleton and the expression levels of *CDH1*, *CDH2* and *VIM* were evaluated. Inhibition of the migration of the three cell lines in the presence of 20 ng/ml EGF was also evaluated using the scratch wound assay method.

Cell proliferation assay

The proliferation of A549, H460 and H1792 cells was evaluated by enzyme immunoassay for bromodeoxyuridine (BrdU) incorporation (BrdU Cell Proliferation Assay Kit; Merck Millipore, Darmstadt, Germany). Cells were seeded in 96-well culture plates at 5,000 cells/well and cultured for 24 hours in culture medium as described above. The cells were then cultured for 48 hours in BrdU-containing medium in the presence or absence of 10–100 µM THC and CBD, individually or in combination (1:1 ratio). Culture medium was removed, the cells were fixed, and BrdU incorporation was evaluated with an anti-BrdU antibody by determining the absorbance at 450/550 nm following the manufacturer's instructions.

Determination of *CB1*, *CB2*, *EGFR*, *CDH1*, *CDH2*, and *VIM* expression levels

Total RNA was extracted from freshly frozen tumor samples and from cell cultures using the TRIzol reagent (Thermo Fischer Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. The RNA concentration was determined by spectrophotometry using a Nanodrop 2000 spectrophotometer (Fischer Scientific, Madrid, Spain). Only extracts with a 260/280 nm ratio > 1.8 were used. RNA integrity was evaluated by capillary electrophoresis using a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only extracts with a RIN of ~10 were used for the determination of gene expression levels.

Random hexamers were used to synthesize complementary DNA (cDNA) using TaqMan RT reagents (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. Gene expression levels were assayed by reverse transcriptase-polymerase chain reaction (RT-PCR) using Assays on Demand for *CB1*, *CB2*, *EGFR*, *CDH1*, *CDH2*, and *VIM* (Applied Biosystems Madrid, Spain). Reactions were carried out in a 7900HT Real-Time Thermocycler (Applied Biosystems, Madrid, Spain). The comparative $\Delta\Delta C_t$ method with glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) as an endogenous control was used to calculate the relative gene expression levels [33]. For human tissue samples *glucuronidase beta* (*GUSB*) gene was used as endogenous control.

Fluorescence staining of F-actin

Filamentous actin (F-actin) in lung cancer cell lines was visualized using rhodamine-conjugated phalloidin (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA). Cells

were cultured on slides to sub-confluence, and exposed to TGF- β (15 ng/mL) in the presence or absence of 10 μ M THC/CBD, which was added 2 hours before TGF- β addition. Control cells received neither TGF- β nor THC/CBD. Forty-eight hours later, the cells were washed twice with pre-warmed phosphate-buffered saline, pH 7.4 (PBS) and fixed in 3.7% formaldehyde in PBS for 10 minutes at room temperature. Next, the cells were permeabilized with 0.1% Triton X-100 in PBS for 3 to 5 minutes. To reduce non-specific background, the samples were pre-incubated with PBS containing 1% bovine serum albumin (BSA) for 20–30 minutes. Next, 5 μ L of phalloidin methanolic stock solution were diluted in 200 μ L PBS for each sample, and the mixture was added to the samples and incubated for 20 minutes. Finally, the samples were washed, the nuclei were stained with 4',6-diamidino-2-phenylindole, and the samples were visualized under a DM2500 fluorescence microscope (Leica, Wetzlar, Germany).

Wound healing assay

The wound healing assay was performed as previously described [34]. A549, H460 and H1792 cells were cultured to confluence in six-well culture plates. Then, cultures were scratched to produce a 'wound' using sterile 10 μ l pipette tips. Cell debris was removed from the culture by washing with sterile PBS for three times. The cells were then cultured in the presence or absence of THC or CBD alone or in combination in serum-free culture medium with 10 ng/ml *EGF* for 48 hours. Images were recorded using a phase contrast photomicroscope (Nikon), and cell migration was quantified with respect to the control (scratched cultures, non-exposed to *EGF* cells) using Scion Image software (Alpha 4.0.3.2).

Data analysis

Comparisons of categorical variables were conducted using the non-parametric Mann–Whitney U test or Kruskal–Wallis test. Survival was analyzed by the Kaplan–Meier method and differences between groups were assessed by log-rank test, performed using SPSS software (IBM Corp., Armonk, NY). A *p*-value of < 0.05 was considered indicative of statistical significance.

In vitro data are shown as means \pm SD and were subjected to analysis of variance (ANOVA) followed by Tukey's multiple-comparison test (GraphPad Software Inc., San Diego, CA, USA). Significance was accepted at *p* < 0.05. The inhibitory concentration 50 (IC₅₀) of THC and CBD, alone or in combination, was calculated according to proliferation data using the Graphpad software.

Results

CB1 and *CB2* overexpression is associated with prolonged survival

First, we evaluated the expression levels of *CB1* and *CB2* in a well-characterized cohort of patients with NSCLC. The clinical and histopathological features of the patients are summarized in Table 1. The expression levels (Δ Ct) of *CB1* and *CB2* were calculated relative to that of the house-keeping gene *glucuronidase beta* (*GUSB*). Multivariate analysis revealed no significant associations between the relative expression levels of *CB1* and *CB2* and the following clinical characteristics: gender (*p* = 0.057 and *p* = 0.267, respectively), progression (*p* = 0.159, *p* = 0.209), age (*p* = 0.690, *p* = 0.835), smoking (*p* = 0.223, *p* = 0.512), stage (*p* = 0.317, *p* = 0.961) and histology (*p* = 0.650, *p* = 0.550). There was a significant association between chronic obstructive pulmonary disease (COPD) and the expression of *CB2* (*p* = 0.020) but not that of *CB1* (*p* = 0.758).

A survival analysis was performed according to the Δ Ct values of *CB1* and *CB2* (Fig 1). Patients with a Δ Ct value of *CB1*, *CB2*, or *CB1* and *CB2* equal to or greater than the mean Δ Ct




Fig 1. Cannabinoid receptors (*CB1* and *CB2*) expression in 157 patients with non-small cell lung cancer (NSCLC). Analysis of the survival of patients with NSCLC according to whether their *CB1* (A), *CB2* (B), or *CB1/CB2* (C) Δ Ct values were higher or lower than the mean Δ Ct value of the entire cohort.

<https://doi.org/10.1371/journal.pone.0228909.g001>

value of the cohort, had longer survival than those with Δ Ct values lower than the mean cohort ($p = 0.035, 0.126, \text{ and } 0.025$, respectively).

THC/CBD inhibited the proliferation and *EGFR* expression in lung cancer cells

Next, we assessed the anti-proliferative effects of THC and CBD on A549, H460 and H1792 cells *in vitro*. The expression of *CB1* was significantly higher than that of *CB2* (6.58 ± 1.29 -fold, $n = 6, p = 0.0136$; 3.15 ± 1.07 -fold, $n = 6, p = 0.0160$; and 2.15 ± 0.45 -fold, $n = 6, p = 0.00247$, for A549, H460 and H1792 cells, respectively). Because of the cytotoxic effects of both compounds at $>100 \mu\text{M}$, detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, THC and CBD concentrations in the range 10–100 μM were used.

THC and CBD separately or in combination significantly inhibited the proliferation of A549 cells in a dose-dependent fashion (Fig 2A). Concentrations of 10–100 μM of both





Fig 2. Tetrahydrocannabinol (THC) and cannabidiol (CBD) inhibit the proliferation and epithelial growth factor receptor (EGFR) expression in lung cancer cells. Proliferation of A549 (A), H460 (B) or H1792 (C) cells treated with 10–100 μM THC, CBD, or CBD/THC. PT (100 μM THC in the presence of PTX 100 ng/ml). PC (100 μM CBD in the presence of PTX 100 ng/ml). PTC (100 μM THC/CBD in the presence of PTX 100 ng/ml). EGFR expression in cells treated with 30 μM THC or CBD, or 10 μM THC/CBD in the presence or absence of 100 ng/mL PTX (D). The results are expressed as mean ± SD of three independent experiments. Each condition was evaluated in six replicates from three independent wells. # $p < 0.05$ versus the control group.


<https://doi.org/10.1371/journal.pone.0228909.g002>

cannabinoid agonists were studied. IC_{50} of 27.25 and 37.31 μM were calculated for THC and CBD, respectively. The combination of both cannabinoids significantly reduces the IC_{50} to 12.94 μM, demonstrating an additive effect. Similar results were founded for H469 cells (IC_{50} of 30.64, 39.78 and 8.04 μM for THC, CBD or THC/CBD, respectively, Fig 2B) and for H1792 cells (IC_{50} of 33.39, 46.41 and 14.55 μM for THC, CBD or THC/CBD respectively, Fig 2C). In all cases, the anti-proliferative effect of THC/CBD was inhibited by pertussis toxin (PTX) at

A549



H460



H1792




Fig 3. THC/CBD inhibits the epithelial-to-mesenchymal transition (EMT) in cancer cells. A549 (A-H), H460 (I-P) and H1792 (Q-X) cells were cultured in the presence or absence of 10 μ M THC/CBD, and/or 15 ng/mL TGF- β . Representative images of cell morphology and fluorescence images of F-actin are shown. All experiments were performed in six replicates and five fields were assessed per condition. Scale bars equal to 25 μ m.

<https://doi.org/10.1371/journal.pone.0228909.g003>

100 ng/mL. According to the calculated IC_{50} values, a dose of 30 μ M for THC and for CBD alone, and 10 μ M for THC combined with CBD were used for subsequent experiments.

Both cannabinoid agonists inhibited the *EGFR* expression in A549, H460 and H1792 cells as it is shown in Fig 2D. Only the combination of THC and CBD significantly decreased *EGFR* expression in A549 and H460 cells, which was inhibited by PTX at 100 ng/mL.

THC/CBD inhibits the EMT in lung cancer cells

A549, H460 and H1792 cells stimulated with TGF- β were used to assess the effect of THC/CBD on the EMT [4, 31, 32]. Cells were stimulated with 15 ng/ml TGF- β in the presence or absence of 10 μ M THC/CBD for 48 hours. Morphological changes were evaluated by phase-contrast light microscopy. Representative results are observed in the Fig 3. Cells exposed to 15 ng/ml TGF- β (Fig 3B, 3J and 3R) became more loosely and acquired a spindle-shaped morphology compared to control cells (Fig 3A, 3I and 3Q). TGF- β -exposed cells treated with 10 μ M THC/CBD suppressed these changes (Fig 3C, 3K and 3S). No effect of 10 μ M THC/CBD was observed in cells not exposed to TGF- β (Fig 3D, 3L and 3T). These effects were found for the three cancer cells included in these experiments. Nevertheless, they were more evident for A549 and H1792 cells than for H460 cells. Changes in cell morphology corresponded to the reorganization of F-actin. In control cells non-exposed to TGF- β or to THC/CBD, phalloidin-labelled F-actin was organized into cortical bundles tightly associated with cell-cell adhesions (Fig 3E, 3M and 3U). After incubation with TGF- β for 48 hours, F-actin was assembled into thicker parallel bundles (actin stress fibers) that crossed the cell surface (Fig 3F, 3N and 3V). These changes were reversed in cultures treated with 10 μ M THC/CBD (Fig 3G, 3O and 3W). Interestingly, A549 cells treated with THC/CBD in the absence of TGF- β showed enhanced cell-cell adhesion and thinner actin bundles than control cells (Fig 3H). This effect was not observed for H460 or H1792 cells, in which no *per se* effect of 10 μ M THC/CBD was observed (Fig 3P and 3X).

The changes observed in cell morphology were consistent with those of the expression of the EMT markers *CDH1*, *CDH2* and *VIM* (Fig 4A–4C). The expression of *CDH1* was significantly downregulated (0.25 \pm 0.15, 0.30 \pm 0.27 and 0.46 \pm 0.19-fold for A549, H460 and H1792 cells, respectively), while that of *CDH2* (6.45 \pm 1.36, 3.86 \pm 1.20 and 2.75 \pm 0.97-fold for A549, H460 and H1792 cells, respectively) and *VIM* (7.59 \pm 0.69, 4.15 \pm 0.20 and 3.91 \pm 0.39-fold for A549, H460 and H1792 cells, respectively) were upregulated in cells stimulated with TGF- β compared to control cells. These changes were significantly reversed by CBD or THC alone (30 μ M) or in combination (10 μ M), which restored the expression values close to those found in treated with CBD or THC but non TGF- β -stimulated cells. The relative expression tendencies found in the three cell types included in this investigation were similar.

Cannabinoids inhibit EGF-induced cell motility in cancer cells

Finally, A549, H460 and H1792 cells were exposed to 20 ng/ml EGF in order to analyze cell migration, as previously reported [34]. As summarized in Fig 5, EGF induces cell migration in the three types of cancer cell used. Both THC and CBD inhibited cell motility, separately or in combination. Although discrete differences were found when comparing data from each cell type, no significant differences were found between them. Inhibition of both cannabinoids tested was close to 30% compared to untreated cells stimulated with EGF.




Fig 4. Tetrahydrocannabinol (THC) and cannabidiol (CBD) inhibit gene expression of EMT-related genes. A549, H460 and H1792 cells were treated with 30 μ M THC or CBD, or 10 μ M THC/CBD and/or 15 ng/ml TGF- β . Relative gene expression levels of *CDH1* (A), *VIM* (B) and *CDH2* (C) were calculated by real-time RT-PCR using *GAPDH* as the endogenous control. The results are means \pm SD of three independent experiments. Each condition was evaluated in six replicates. The comparative $\Delta\Delta$ Ct method was used to analyze the data. # $p < 0.05$ versus the control group.

<https://doi.org/10.1371/journal.pone.0228909.g004>

Discussion

NSCLC is the leading cause of cancer-related mortality in the United States [1–2]. It is an aggressive disease strongly associated with smoking that frequently disseminates; thus, patients are commonly diagnosed with metastatic lesions. Early trials established that radiotherapy was more effective than surgery [35], but due to the extremely low survival rates, chemotherapy has emerged as the optimal modality of treatment. NSCLC is characterized by overactivity of *EGFR*, which could explain the limited efficacy of chemotherapy [36]. Regrettably, the use of selective *EGFR* inhibitors or monoclonal antibodies against *EGFR* has failed, so other therapies for NSCLC are under investigation [36]. Among them, the use of cannabinoids is being evaluated using *in vivo* and *in vitro* models of breast, prostate, and lung cancer [37]. Cannabinoids activate the specific G-protein coupled receptors *CB1* and *CB2*. Although *CB1* expression has been associated with the brain, and that of *CB2* with the immune system, both receptors are expressed to some degree in other cells and organs (e.g., placenta, liver, endothelial cells, smooth muscle cells, and kidney). Although the expression of *CB1* and *CB2* in NSCLC has been evaluated, to our knowledge, no study has explored the correlation between their expression levels and the clinical and histopathological features of patients with NSCLC. In this study, only COPD was significantly associated with the expression of *CB2* ($p = 0.020$), and non-significantly with that of *CB1* ($p = 0.758$). *CB2* is reported to be related to smoking; for example, nicotine addiction is inhibited by *CB2* antagonists in mice [38] and the level of *CB2* mRNA in blood increases after cessation of marijuana smoking [39]. As smoking is the main causative agent of COPD, further studies of this association are needed to enhance our understanding of the relationship between COPD and lung cancer [40].

The few studies of the prognostic value of *CB* expression have reported discrepant results [41]. In tumors of the nervous system, there is a relationship between high expression of *CB1* and *CB2* with astrocytoma, and of *CB2* with glioblastoma and malignancy [42–43]. In contrast, high expression of *CB2* is associated with an increase of macrophage invasion of brain tumors [44]. In fact, high expression of *CB1* is associated with increased severity of prostate and colorectal cancer [45–46]. In contrast, high expression of *CB1* and *CB2* indicates longer disease-free survival in patients with hepatocellular carcinoma [47], while a lower expression of *CB1* is correlated with a lower survival in patients with pancreatic ductal carcinoma [48]. In the present study, NSCLC patients with high expression of *CB1* and *CB2* showed prolonged survival, which supports their potential use as biomarkers.

Cannabinoids inhibit the proliferation of breast, prostate, and bone cancer cells [31]. However, little is known about the beneficial effects of THC/CBD. Our results indicate that THC and CBD inhibit cell proliferation in a dose-dependent manner. Moreover, CBD enhances the antiproliferative effect of THC in A549, H460 and H1792 cells, in agreement with previous reports [24–27]. CBD and THC also reduce *EGFR* expression in the three types of cells analyzed in this study. Both cannabinoids are known to inhibit the *EGFR* pathway, which modulates the proliferation of tumor cells [49–50].

Lung cancer has a propensity to disseminate and invade other tissues [49]. THC inhibits *EGFR*-induced migration of A549 cells and subcutaneous metastasis in mice with severe combined immunodeficiency [50]. Our results concerning cell migration are in line with those




Fig 5. Tetrahydrocannabinol (THC) and cannabidiol (CBD) inhibit EGF-induced cell migration in cancer cells. A549, H460 and H1792 cells were cultured until confluence. Scratching was performed and the cells were cultured in the presence or absence of 30 μM THC or CBD, or 10 μM THC/CBD. Twenty ng/ml EGF was used to induce cell migration. Cells were cultured for 48 hours. Phase-contrast images were collected of 5 fields from each well. Representative images are shown. Total wound areas were measured using Scion Image software, and the percentage of wound recolonization was calculated. The results are means ± SD of three independent experiments. # *p* < 0.05 versus the control group. Scale bars equal to 50 μm.

<https://doi.org/10.1371/journal.pone.0228909.g005>

previously reported. Both cannabinoid agonists inhibited EGF-mediated cell migration in A549, H460 and H1792 cells. CBD has an additive effect on the inhibition of THC-mediated cell migration, which supports the beneficial use of both cannabinoids in combination. The metastasis of epithelial tumors involves a series of phenotypic changes, known as the EMT. Cannabinoids have been reported to inhibit EMT in gastric, endometrial and NSCLC cancer cells [4, 34,51]. However, this important property of cannabinoids has not been extensively investigated. For this reason, we explored the effect of THC/CBD on EMT in cancer cells treated with TGF- β *in vitro*. The combination of THC/CBD strongly affects the cytoskeletal and molecular changes characteristics of EMT, including the downregulation of *CDH1* and the upregulation of *CDH2* and *VIM*. Interestingly, in A549 cells, in the absence of TGF- β , exposed to CBD and THC, increased cell-cell adhesion and reduced thickness of actin bundles compared to control cells was observed. These effects could be explained by the mesenchymal phenotype of A549 cells, which are of epithelial origin; indeed, these cells produce TGF- β [52]. Therefore, THC and CBD suppress the basal EMT phenotype, which enhances the medical importance of cannabinoids.

In summary, our results indicate that *CB1* and *CB2* expression levels have potential as biomarkers for the survival of patients with NSCLC, and that THC and CBD could be used to suppress cell proliferation and EMT. Moreover, the combined use of both compounds could be of interest due to the additive effects observed and could minimize the undesired effects of THC.

Author Contributions

Conceptualization: Lara Milian, Manuel Mata, José Galbis, Carmen Carda.

Data curation: Lara Milian, Manuel Mata, Javier Alcacer, Carlos Camps, José Galbis.

Formal analysis: Lara Milian, María Sancho-Tello.

Funding acquisition: Manuel Mata, Carlos Camps, José Galbis, Julian Carretero, Carmen Carda.

Investigation: Lara Milian, Manuel Mata, María Oliver, María Sancho-Tello, José Galbis, Julian Carretero, Carmen Carda.

Methodology: Lara Milian, Manuel Mata, Javier Alcacer, María Oliver, Carlos Camps, Carmen Carda.

Project administration: Manuel Mata.

Supervision: Manuel Mata, María Sancho-Tello, José Javier Martín de Llano, Carmen Carda.

Validation: Manuel Mata, María Oliver.

Writing – original draft: Manuel Mata, Carmen Carda.

Writing – review & editing: Manuel Mata, María Sancho-Tello, José Javier Martín de Llano, Carmen Carda.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011; 61(2):69–90. <https://doi.org/10.3322/caac.20107> PMID: 21296855
2. Youlten DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: Geographical distribution and secular trends. *J Thorac Oncol.* 2008; 3(8):819–31. <https://doi.org/10.1097/JTO.0b013e31818020eb> PMID: 18670299
3. Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. *J Thorac Dis.* 2013; 5 Suppl 5:S479–90.

4. Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. *Mol Carcinog*. 2016; 55(12):2063–76. <https://doi.org/10.1002/mc.22451> PMID: 26741322
5. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. *Semin Oncol*. 2002; 29(1 Suppl 4):3–14.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol*. 1995; 19(3):183–232. [https://doi.org/10.1016/1040-8428\(94\)00144-i](https://doi.org/10.1016/1040-8428(94)00144-i) PMID: 7612182
7. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev Res (Phila)*. 2011; 4(1):65–75.
8. Fowler CJ, Hammarsten P, Bergh A. Tumour cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer. *PLoS One*. 2010; 5(12):e15205. <https://doi.org/10.1371/journal.pone.0015205> PMID: 21203460
9. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? *Prog Lipid Res*. 2011; 50(2):193–211. <https://doi.org/10.1016/j.plipres.2011.01.001> PMID: 21295074
10. Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of cannabidiol in breast cancer. *Mol Oncol*. 2015; 9(4):906–19. <https://doi.org/10.1016/j.molonc.2014.12.010> PMID: 25660577
11. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol*. 2005; 144(8):1032–6. <https://doi.org/10.1038/sj.bjp.0706134> PMID: 15700028
12. Jung CK, Kang WK, Park JM, Ahn HJ, Kim SW, Taek Oh S et al. Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. *Oncol Lett*. 2013; 5(3):870–6. <https://doi.org/10.3892/ol.2012.1081> PMID: 23426698
13. Marshall AD, Lagutina I, Grosveld GC. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. *Cancer Res*. 2011; 71(24):7471–80. <https://doi.org/10.1158/0008-5472.CAN-11-0924> PMID: 22037868
14. Cipriano M, Häggström J, Hammarsten P, Fowler CJ. Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer. *PLoS One*. 2013; 8(6):e65798. <https://doi.org/10.1371/journal.pone.0065798> PMID: 23755281
15. Ravi J, Sneha A, Shilo K, Nasser MW, Ganju RK. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. *Oncotarget*. 2014; 5(9):2475–86. <https://doi.org/10.18632/oncotarget.1723> PMID: 24811863
16. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. *Cancer Lett*. 2009; 285(1):6–12. <https://doi.org/10.1016/j.canlet.2009.04.005> PMID: 19442435
17. Bifulco M, Laezza C, Pisanti S, Gazerro P. Cannabinoids and cancer: Pros and cons of an anti-tumour strategy. *Br J Pharmacol*. 2006; 148(2):123–35. <https://doi.org/10.1038/sj.bjp.0706632> PMID: 16501583
18. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L et al. Control by the endogenous cannabinoid system of *ras* oncogene-dependent tumor growth. *FASEB J*. 2001; 15(14):2745–7. <https://doi.org/10.1096/fj.01-0320fje> PMID: 11687506
19. Booth JK, Bohlmann J. Terpenes in Cannabis sativa—From plant genome to humans. *Plant Sci*. 2019; 284:67–72. <https://doi.org/10.1016/j.plantsci.2019.03.022> PMID: 31084880
20. McAllister SD, Soroceanu L, Desprez PY. The antitumor activity of plant-derived non-psychoactive cannabinoids. *J Neuroimmune Pharmacol*. 2015; 10(2):255–67. <https://doi.org/10.1007/s11481-015-9608-y> PMID: 25916739
21. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. *Addict Biol*. 2000; 5(1):37–46. <https://doi.org/10.1080/13556210071252> PMID: 20575818
22. Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. *Ther Adv Neurol Disord*. 2016; 9(1):9–30.
23. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*. 2001; 134(4):845–52. <https://doi.org/10.1038/sj.bjp.0704327> PMID: 11606325
24. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of delta(9)-tetrahydrocannabinol.

- Drug Alcohol Depend. 2008; 94(1–3):191–8. <https://doi.org/10.1016/j.drugalcdep.2007.11.017> PMID: [18206320](https://pubmed.ncbi.nlm.nih.gov/18206320/)
25. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer*. 2012; 12(6):436–44. <https://doi.org/10.1038/nrc3247> PMID: [22555283](https://pubmed.ncbi.nlm.nih.gov/22555283/)
 26. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as a potential anticancer drug. *Br J Clin Pharmacol*. 2013; 75(2):303–12. <https://doi.org/10.1111/j.1365-2125.2012.04298.x> PMID: [22506672](https://pubmed.ncbi.nlm.nih.gov/22506672/)
 27. Guindon J, Hohmann AG. The endocannabinoid system and cancer: Therapeutic implications. *Br J Pharmacol*. 2011; 163(7):1447–63. <https://doi.org/10.1111/j.1476-5381.2011.01327.x> PMID: [21410463](https://pubmed.ncbi.nlm.nih.gov/21410463/)
 28. Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol Cancer Ther*. 2011; 10(1):90–103. <https://doi.org/10.1158/1535-7163.MCT-10-0688> PMID: [21220494](https://pubmed.ncbi.nlm.nih.gov/21220494/)
 29. Kim EJ, Kim HJ, Park MK, Kang GJ, Byun HJ, Lee H et al. Cardamonin suppresses TGF- β -induced epithelial mesenchymal transition via restoring protein phosphatase 2A expression. *Biomol Ther (Seoul)*. 2015; 23(2):141–8.
 30. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? *Nat Rev Cancer*. 2007; 7(6):415–28. <https://doi.org/10.1038/nrc2131> PMID: [17508028](https://pubmed.ncbi.nlm.nih.gov/17508028/)
 31. Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH et al. Transforming growth factor beta 1 induces epithelial-to-mesenchymal transition of A549 cells. *J Korean Med Sci*. 2007; 22(5):898–904. <https://doi.org/10.3346/jkms.2007.22.5.898> PMID: [17982242](https://pubmed.ncbi.nlm.nih.gov/17982242/)
 32. Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, Watabe T et al. TGF- β -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. *J Biochem*. 2012; 151(2):205–16. <https://doi.org/10.1093/jb/mvr136> PMID: [22161143](https://pubmed.ncbi.nlm.nih.gov/22161143/)
 33. Mata M, Sarriá B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human epithelial cells. *Thorax*. 2005; 60(2):144–52. <https://doi.org/10.1136/thx.2004.025692> PMID: [15681504](https://pubmed.ncbi.nlm.nih.gov/15681504/)
 34. Xian X, Huang L, Zhang B, Wu C, Cui J, Wang Z. WIN 55,212–2 inhibits the epithelial mesenchymal transition of gastric cancer cells via COX-2 signals. *Cell Physiol Biochem*. 2016; 39(6):2149–57. <https://doi.org/10.1159/000447910> PMID: [27802436](https://pubmed.ncbi.nlm.nih.gov/27802436/)
 35. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. *Transl Lung Cancer Res*. 2016; 5(3):288–300. <https://doi.org/10.21037/tlcr.2016.06.07> PMID: [27413711](https://pubmed.ncbi.nlm.nih.gov/27413711/)
 36. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. *J Thorac Dis*. 2010; 2(1):48–51. PMID: [22263017](https://pubmed.ncbi.nlm.nih.gov/22263017/)
 37. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. *Cancer Metastasis Rev*. 2011; 30(3–4):599–612. <https://doi.org/10.1007/s10555-011-9318-8> PMID: [22038019](https://pubmed.ncbi.nlm.nih.gov/22038019/)
 38. Ignatowska-Jankowska BM, Muldoon PP, Lichtman AH, Damaj MI. The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. *Psychopharmacology (Berl)*. 2013; 229(4):591–601.
 39. Muhl D, Kathmann M, Hoyer C, Kranaster L, Hellmich M, Gerth CW et al. Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. *Naunyn Schmiedebergs Arch Pharmacol*. 2014; 387(7):691–5. <https://doi.org/10.1007/s00210-014-0984-2> PMID: [24788457](https://pubmed.ncbi.nlm.nih.gov/24788457/)
 40. Mouronte-Roibás C, Leiro-Fernández V, Fernández-Villar A, Botana-Rial M, Ramos-Hernández C, Ruano-Ravina A. COPD, emphysema and the onset of lung cancer. A systematic review. *Cancer Lett*. 2016; 382(2):240–4. <https://doi.org/10.1016/j.canlet.2016.09.002> PMID: [27666776](https://pubmed.ncbi.nlm.nih.gov/27666776/)
 41. Pyszniak M, Tabarkiewicz J, Łuszczki JJ. Endocannabinoid system as a regulator of tumor cell malignancy—biological pathways and clinical significance. *Onco Targets Ther*. 2016; 9:4323–36. <https://doi.org/10.2147/OTT.S106944> PMID: [27486335](https://pubmed.ncbi.nlm.nih.gov/27486335/)
 42. Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G et al. Inhibition of glioma growth *in vivo* by selective activation of the CB(2) cannabinoid receptor. *Cancer Res*. 2001; 61(15):5784–9. PMID: [11479216](https://pubmed.ncbi.nlm.nih.gov/11479216/)
 43. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. *Brain Res*. 2007; 1137(1):161–9. <https://doi.org/10.1016/j.brainres.2006.12.060> PMID: [17239827](https://pubmed.ncbi.nlm.nih.gov/17239827/)
 44. De Jesús ML, Hostalot C, Garibi JM, Sallés J, Meana JJ, Callado LF. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. *Neurochem Int*. 2010; 56(6–7):829–33. <https://doi.org/10.1016/j.neuint.2010.03.007> PMID: [20307616](https://pubmed.ncbi.nlm.nih.gov/20307616/)

45. Gustafsson SB, Palmqvist R, Henriksson ML, Dahlin AM, Edin S, Jacobsson SO et al. High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II micro-satellite stable colorectal cancer. *PLoS One*. 2011; 6(8):e23003. <https://doi.org/10.1371/journal.pone.0023003> PMID: [21901119](https://pubmed.ncbi.nlm.nih.gov/21901119/)
46. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L et al. A high cannabinoid CB (1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. *Eur J Cancer*. 2009; 45(1):174–82. <https://doi.org/10.1016/j.ejca.2008.10.010> PMID: [19056257](https://pubmed.ncbi.nlm.nih.gov/19056257/)
47. Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet*. 2006; 171(1):31–8. <https://doi.org/10.1016/j.cancergencyto.2006.06.014> PMID: [17074588](https://pubmed.ncbi.nlm.nih.gov/17074588/)
48. Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. *Int J Cancer*. 2008; 122(4):742–50. <https://doi.org/10.1002/ijc.23114> PMID: [17943729](https://pubmed.ncbi.nlm.nih.gov/17943729/)
49. Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of cannabidiol in breast cancer. *Mol Oncol*. 2015; 9(4):906–19. <https://doi.org/10.1016/j.molonc.2014.12.010> PMID: [25660577](https://pubmed.ncbi.nlm.nih.gov/25660577/)
50. Preet A, Ganju RK, Groopman JE. Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration *in vitro* as well as its growth and metastasis *in vivo*. *Oncogene*. 2008; 27(3):339–46. <https://doi.org/10.1038/sj.onc.1210641> PMID: [17621270](https://pubmed.ncbi.nlm.nih.gov/17621270/)
51. Zhang Y, Zheng W, Shen K, Shen W. Δ^9 -Tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer. *Oncol Lett*. 2018; 15(6):8527–35. <https://doi.org/10.3892/ol.2018.8407> PMID: [29805589](https://pubmed.ncbi.nlm.nih.gov/29805589/)
52. Koyama S, Sato E, Nomura H, Kubo K, Nagai S, Izumi T. Type II pneumocytes release chemoattractant activity for monocytes constitutively. *Am J Physiol*. 1997; 272(5 Pt 1):L830–7.